Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity

• DOI: 10.1038/srep43940
• Publication Date: 2017-03-07T10:41:59Z
• Authors: Wenwen Gu; Wenping Xu; Xiaoxi Sun; Bubing Zeng; Shuangjie Wang; Nian Dong; Xu Zhang; Chengshui Chen; Long Yang; Guowu Chen; Aijie Xin; Zhong Ni; Jian Wang; Jun Yang
• Keywords: 0301 basic medicine; Mice, Inbred ICR; Norandrostanes; Antineoplastic Agents, Hormonal; Mice, Nude; Contraceptives, Oral, Synthetic; Article; Endometrial Neoplasms; 3. Good health; Tamoxifen; 03 medical and health sciences; Treatment Outcome; Non-alcoholic Fatty Liver Disease; Cell Line, Tumor; Animals; Heterografts; Humans; Female; Neoplasm Transplantation

Abstract Tamoxifen is administered for estrogen receptor positive (ER + ) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER than five such treatment. was also approved by the FDA as a chemopreventive agent those deemed at high risk development cancer. The side effects are substantial concern because these extended methods administration. In this study, we found that anordrin, marketed an antifertility medicine in China, inhibited tamoxifen-induced epithelial cell mitosis NAFLD mouse uterus anti-estrogenic estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, active metabolite weakly bound to ligand binding domain ER-α. Anordrin did not regulate classic nuclear pathway; thus, affect anti-tumor activity nude mice. Taken together, data suggested anordrin could eliminate without affecting its activity.